Project Grant W81XWH1910238

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $190,485.00 to support a 5-year research project investigating the molecular mechanisms underlying differentiation failure in neuroepithelial stem cells with NF2 mutations. The goal is to identify the cellular origins of spinal ependymoma tumors in patients with NF2...

The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $858,033 Project Grant to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant, titled "TARGETING SCHWANN CELL-IMMUNE INTERACTIONS IN NEUROFIBROMATOSIS TYPE 1", will fund research focused on improving treatment approaches for neurofibromatosis type 1, a genetic disorder that causes tumor growth in the nervous system. The grant award period runs from...

This $877,001 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports a research initiative aimed at elucidating the cellular and molecular mechanisms underlying the clinical heterogeneity observed in Neurofibromatosis Type 1 (NF1). Specifically, the project will leverage patient-derived induced pluripotent stem cells, primary...

The University of Texas Southwestern Medical Center will target fibrosis in neurofibromas to reduce tumor mass and enhance response to MEK inhibitors under a $860,773 project grant from the Department of the Army Medical Command. Funded through the Military Medical Research and Development program, this three-year award will support the awardee's efforts to transform Service Member healthcare and investigate medical solutions for the battlefield by developing innovative approaches for treating...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $734,542 to Ann & Robert H. Lurie Children's Hospital of Chicago to conduct research on developing novel biomarkers for plexiform neurofibroma tumor burden in neurofibromatosis type 1 (NF1) patients. The key objectives are to: 1) Perform analytical validation studies of...

The federal Project Grant award R01NS133200, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research focused on identifying germline modifiers of tumors associated with Neurofibromatosis Type 1 (NF1). The total grant funding is $656,513, awarded on September 10, 2024, with a completion date of August 31, 2029. The research aims to expand the...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $635,173 to support research on understanding the mechanisms by which the MYCN oncogene drives an immunosuppressive tumor microenvironment in high-risk neuroblastoma. The key products or services to be delivered under this grant include: Characterizing the types and...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $225,101 to Baylor College of Medicine to conduct research aimed at understanding how the MYCN oncogene drives an immune-suppressive tumor microenvironment in neuroblastoma. The key objectives are to: 1) determine how MYCN rewires T cell metabolism to promote immune suppression, and 2) elucidate how MYCN-induced lipogenesis contributes to a suppressive tumor immune...

The National Cancer Institute (NCI) awarded a $293,369 Project Grant (CFDA 93.398 - Cancer Research Manpower) to Duke University to investigate the mechanisms by which residual tumor cells evade the immune system after oncogene-targeted cancer therapies. The research aims to uncover potential targets and approaches to enhance the immune-mediated clearance of these residual cells, which often serve as the reservoir for treatment resistance and relapse. Using mouse melanoma models and human cancer...

This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) in the amount of $431,968 is supporting research to elucidate how the oncogene MYCN rewires the metabolic environment of neuroblastoma tumors to drive immune suppression. The research aims to modulate the metabolic environment of MYCN-driven neuroblastoma tumors to enhance immune-based treatment approaches for this high-risk cancer. The research is being conducted by the prime...